Katarina Davalieva

Dr. Katarina Davalieva

Macedonian Academy of Sciences and Arts, Skopje, North Macedonia
orcid
Senior researcher with extensive experience in genetics, mol...

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2016 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
Katarina DavalievaKatarina Davalieva
Katarina Davalieva
IKIvana Maleva Kostovska
Ivana Maleva Kostovska
ADAndrew J. Dwork
Andrew J. Dwork
Despite intense scientific efforts, the neuropathology and pathophysiology of schizophrenia are poorly understood. Proteomic studies, by testing large numbers of proteins for associations with disease, may contribute to the understanding of the molecular mechanisms of schizophrenia. They may also indicate the types and locations of cells most likely to harbor pathological alterations. Investigations using proteomic approaches have already provided much information on quantitative and qualitative protein patterns in postmortem brain tissue, peripheral tissues and body fluids. Different proteomic technologies such as 2-D PAGE, 2-D DIGE, SELDI-TOF, shotgun proteomics with label-based (ICAT) and label-free (MSE) quantification have been applied to the study of schizophrenia for the past 15 years. In this article, we compare proteomic studies of schizophrenia with reports of quantitative studies of cell-type specific expression. This review summarizes the results, mostly from brain but also from other tissues and bodily fluids, of proteomics studies in schizophrenia. Emphasis is given to proteomics platforms, varying sources of material, proposed candidate biomarkers emerging from comparative proteomics studies, and the specificity of the putative markers in terms of other mental illnesses. We also compare proteins altered in schizophrenia with reports of protein or mRNA sequences that are relatively enriched in specific cell types. While proteomic studies of schizophrenia find abnormalities in the expression of many proteins that are not cell type-specific, there appears to be a disproportionate representation of proteins whose synthesis and localization are highly enriched in one or more brain cell type compared with other types of brain cells. Two of the three proteins most commonly altered in schizophrenia are aldolase C and glial fibrillary acidic protein, astrocytic proteins with entirely different functions, but the studies are approximately evenly divided with regard to the direction of the differences and the concordance or discordance between the two proteins. Alterations of common myelin-associated proteins were also frequently observed, and in four studies that identified alterations in at least two, all differences were downwards in schizophrenia, consistent with earlier studies examining RNA or targeting myelin-associated proteins.

12 June 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
Katarina DavalievaKatarina Davalieva
Katarina Davalieva
IKIvana Maleva Kostovska
Ivana Maleva Kostovska
SKSanja Kiprijanovska
Sanja Kiprijanovska
KMKaterina Markoska
Katerina Markoska
KKKaterina Kubelka-Sabit
Katerina Kubelka-Sabit
MPMomir Polenakovic
Momir Polenakovic

29 January 2015 in Proteome Science
Verified
Journal Article
Open access
PDF file
Katarina DavalievaKatarina Davalieva
Katarina Davalieva
SKSanja Kiprijanovska
Sanja Kiprijanovska
SKSelim Komina
Selim Komina
GPGordana Kiro Petrushevska
Gordana Kiro Petrushevska
NZNatasha Chokrevska Zografska
Natasha Chokrevska Zografska
MPMomir Polenakovic
Momir Polenakovic
Despite the overall success of prostate specific antigen (PSA) in screening and detection of prostate cancer (PCa), its use has been limited due to the lack of specificity. The principal driving goal currently within PCa research is to identify non-invasive biomarker(s) for early detection of aggressive tumors with greater sensitivity and specificity than PSA. In this study, we focused on identification of non-invasive biomarkers in urine with higher specificity than PSA. We tested urine samples from PCa and benign prostatic hyperplasia (BPH) patients by 2-D DIGE coupled with MS and bioinformatics analysis. Statistically significant (p < 0.05), 1.8 fold variation or more in abundance, showed 41 spots, corresponding to 23 proteins. The Ingenuity Pathway Analysis showed significant association with the Acute Phase Response Signaling pathway. Nine proteins with differential abundances were included in this pathway: AMBP, APOA1, FGA, FGG, HP, ITIH4, SERPINA1, TF and TTR. The expression pattern of 4 acute phase response proteins differed from the defined expression in the canonical pathway. The urine levels of TF, AMPB and HP were measured by immunoturbidimetry in an independent validation set. The concentration of AMPB in urine was significantly higher in PCa while levels of TF and HP were opposite (p < 0.05). The AUC for the individual proteins ranged from 0.723 to 0.754. The combination of HP and AMBP yielded the highest accuracy (AUC = 0.848), greater than PSA. The proposed biomarker set is quickly quantifiable and economical with potential to improve the sensitivity and specificity of PCa detection.

31 January 2012 in Andrologia
Verified
Journal Article
Closed access
PDF file
Katarina DavalievaKatarina Davalieva
Katarina Davalieva
SKS. Kiprijanovska
S. Kiprijanovska
PNP. Noveski
P. Noveski
TPT. Plaseski
T. Plaseski
BKB. Kocevska
B. Kocevska
DPDijana Plaseska-Karanfilska
Dijana Plaseska-Karanfilska
Seminal plasma is a potential source of biomarkers for many disorders of the male reproductive system including male infertility. The identification and characterisation of differentially expressed proteins in seminal plasma of man with normal and impaired spermatogenesis can help in the elucidation of the molecular basis of male infertility. We compared the protein expression profiles of seminal plasma from four different groups of men as follows: normozoospermic, asthenozoospermic, oligozoospermic and azoospermic groups, using two-dimensional differential gel electrophoresis (2-D DIGE). We found eight proteins with statistically significant increased expression in azoospermia compared with at least one of the other studied groups. The differentially expressed spots were fibronectin, prostatic acid phosphatase (PAP), proteasome subunit alpha type-3, beta-2-microglobulin, galectin-3-binding protein, prolactin-inducible protein and cytosolic nonspecific dipeptidase. Notably, PAP was increased in patients with azoospermia compared with that of all other groups. We have observed no statistically significant differences in protein expression between three of the groups: normozoospermic, oligozoospermic and asthenozoospermic. We suggest that the identified panel of proteins in our study especially PAP have a strong potential to be used as azoospermia markers. However, further investigations will be necessary to validate these markers in samples of larger and independent patient cohorts and to clarify their role in the pathogenesis of male infertility.

29 December 2017 in Proteomes
Verified
Journal Article
Open access
PDF file
Katarina DavalievaKatarina Davalieva
Katarina Davalieva
SKSanja Kiprijanovska
Sanja Kiprijanovska
IKIvana Maleva Kostovska
Ivana Maleva Kostovska
SSSotir Stavridis
Sotir Stavridis
OSOliver Stankov
Oliver Stankov
MPMomir Polenakovic
Momir Polenakovic
Detecting prostate cancer (PCa) using non-invasive diagnostic markers still remains a challenge. The aim of this study was the identification of urine proteins that are sufficiently sensitive and specific to detect PCa in the early stages. Comparative proteomics profiling of urine from patients with PCa, benign prostate hyperplasia, bladder cancer, and renal cancer, coupled with bioinformatics analysis, were performed. Statistically significant difference in abundance showed 20 and 85 proteins in the 2-D DIGE/MS and label-free LC-MS/MS experiments, respectively. In silico analysis indicated activation, binding, and cell movement of subset of immune cells as the top affected cellular functions in PCa, together with the down-regulation of Acute Phase Response Signaling and Liver X Receptor/ Retinoid X Receptor (LXR/RXR) activation pathways. The most promising biomarkers were 35, altered in PCa when compared to more than one group. Half of these have confirmed localization in normal or PCa tissues. Twenty proteins (CD14, AHSG, ENO1, ANXA1, CLU, COL6A1, C3, FGA, FGG, HPX, PTGDS, S100A9, LMAN2, ITIH4, ACTA2, GRN, HBB, PEBP1, CTSB, SPP1) are oncogenes, tumor suppressors, and multifunctional proteins with highly confirmed involvement in PCa, while 9 (AZU1, IGHG1, RNASE2, PZP, REG1A, AMY1A, AMY2A, ACTG2, COL18A1) have been associated with different cancers, but not with PCa so far, and may represent novel findings. LC-MS/MS data are available via ProteomeXchange with identifier PXD008407.

7 November 2023 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
MAMichal Alexovič
Michal Alexovič
CUCsilla Uličná
Csilla Uličná
JSJán Sabo
Ján Sabo
Katarina DavalievaKatarina Davalieva
Katarina Davalieva